

# From sample to treatment Preclinical Factors

#### **Rikke Fredslund Andersen**

Biochemistry and Immunology
University Hospital of Southern Denmark, Vejle
rikke.fredslund.andersen@rsyd.dk








## Variation



#### Pre-analytical variation



#### **Total variation**

- I. Biological variation, co-morbidities, physical activity, fasting, timing in relation to medical/surgical treatment
- II. Collection tube (type/volume), syringe, stasis, first/second tube, agitation
- III. Time to centrifugation, centrifugation, temperature, pipetting, storage conditions, freeze/thaw
- IV. Extraction of DNA, (pre-amplification, denaturation, bisulphite conversion,...)










- Biological variation, co-morbidities, physical activity, fasting, timing in relation to medical/surgical treatment
- II. Collection tube (type/volume), syringe, stasis, first/second tube, agitation
- III. Time to centrifugation, centrifugation, temperature, pipetting, storage conditions, freeze/thaw
- IV. Extraction of DNA, (pre-amplification, denaturation, bisulphite conversion,...)



Yuwono et al. eLife 2021;0:e69679.







## Surgical treatment





## The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA

Tenna V. Henriksen<sup>1</sup>, Thomas Reinert<sup>1</sup>, Emil Christensen<sup>1</sup>, Himanshu Sethi<sup>2</sup>, Karin Birkenkamp-Demtröder<sup>1</sup>, Mikail Gögenur<sup>3</sup>, Ismail Gögenur<sup>3</sup>, Bernhard G. Zimmermann<sup>2</sup>, The IMPROVE Study Group<sup>†</sup>, Lars Dyrskjøt<sup>1</sup> and Claus L. Andersen<sup>1</sup>

- 1 Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark
- 2 Natera Inc., San Carlos, CA, USA
- 3 Center for Surgical Sciences, Zealand University Hospital, Køge, Denmark

Molecular Oncology 14 (2020) 1670-1679 (













#### Medical treatment











On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer


Tina Moser 10, Julie Waldispuehl-Geigl 10, Jelena Belic 19, Sabrina Weber 1, Qing Zhou 1, Samantha O. Hasenleithner 10, Ricarda Graf 1, Jasmin Alia Terzic 2, Florian Posch 2, Heinz Sill 3, Sigurd Lax 6, Karl Kashofer 5, Gerald Hoefler 5, Helmut Schoellnast 6, Ellen Heitzer 10, Jochen B. Geigl 10, Thomas Bauernhofer 10, Samantha O. Hasenleithner 10, Ricarda Graf 1, Jochen B. Geigl 10, Thomas Bauernhofer 10, Samantha O. Hasenleithner 10, Ricarda Graf 1, Jochen B. Geigl 10, Thomas Bauernhofer 10, Samantha O. Hasenleithner 10, Ricarda Graf 1, Julia Waldispuehl-Geigl 10, Ricarda Graf 10,

npj Precision Oncology 4:30 (2020)



### Variation





#### **Total variation**

- I. Biological variation, co-morbidities, physical activity, fasting, timing in relation to medical/surgical treatment
- II. Collection tube (type/volume), syringe, stasis, first/second tube, agitation
- III. Time to centrifugation, centrifugation, temperature, pipetting, storage conditions, freeze/thaw
- IV. Extraction of DNA, (pre-amplification, denaturation, bisulphite conversion,...)








## EDTA vs. Streck tubes





Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients

Bente Risberg, \*<sup>15</sup> Dana W.Y. Tsui, \*<sup>1</sup> Heather Biggs, \*<sup>1</sup> Andrea Ruiz-Valdepenas Martin de Almagro, \*<sup>15</sup> Sarah-Jane Dawson, \*<sup>16</sup> Charlotte Hodgkin, \*<sup>1</sup> Linda Jones, \*<sup>1</sup> Christine Parkinson, \*<sup>1</sup> Anna Piskorz, \*<sup>1</sup> Francesco Marass, \*<sup>1</sup> Dineika Chandrananda, \*<sup>1</sup> Elizabeth Moore, \*<sup>1</sup> James Morris, \*<sup>1</sup> Vincent Plagnol, \*\* Nitzan Rosenfeld, \*<sup>1</sup> Carlos Caldas, \*<sup>1</sup> James D. Brenton, \*<sup>11</sup> and Davina Gale\*

The Journal of Molecular Diagnostics, Vol. 20, No. 6, November 2018







## Volume of blood


Vejle Hospital
- part of Lillebaelt Hospital

Region of Southern Denmark

- Organ
- Stage
- Metastatic site


Liu MC et al., Ann Onc 2020


















## Metastatic site - CRC














### **Variation**





#### **Total variation**

- I. Biological variation, co-morbidities, physical activity, fasting, timing in relation to medical/surgical treatment
- II. Collection tube (type/volume), syringe, stasis, first/second tube, agitation
- III. Time to centrifugation, centrifugation, temperature, pipetting, storage conditions, freeze/thaw
- IV. Extraction of DNA, (pre-amplification, denaturation, bisulphite conversion,...)









## Blood sampling

- Tube type (EDTA, Streck, Paxgene)
- Processing (centrifugation (single/double), timing, pipetting)
- Storage of plasma / purified cfDNA (tubes, duration, freeze/thaw cycles)

#### ISO 20186-3:2019

Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood — Part 3: Isolated circulating cell free DNA from plasma







# ISO20186-3

	WARRING STREET, STREET
Vejle Hospital - part of Lillebaelt Hospital	THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAM

5	Outside the laboratory					
	5.1	Specimen collection	5			
		5.1.1 Information about the specimen donor/patient	5			
		5.1.2 Selection of the venous whole blood collection tube by the laboratory	6			
		5.1.3 Venous whole blood collection from the donor/patient and stabilization				
		procedures	6			
		5.1.4 Information about the specimen and storage requirements at the blood				
		collection facility Transport requirements	7			
	5.2	Transport requirements	7			
6	Insid	e the laboratory	8			
	6.1	e the laboratory	8			
	6.2	Storage requirements for blood specimens	8			
	6.3	Plasma preparation	9			
	6.4	Storage requirements for plasma samples	9			
	6.5	Isolation of the ccfDNA				
		6.5.1 General	10			
		6.5.2 Using blood collection tubes with stabilizers	10			
		6.5.3 Using blood collection tubes without stabilizers	11			
	6.6	Quantity and quality assessment of isolated ccfDNA	11			
	6.7	Storage of isolated ccfDNA				
		6.7.1 General				
		6.7.2 ccfDNA isolated with commercially available kits	12			
		6.7.3 ccfDNA isolated with the laboratory's own protocols	12			










Yuwono et al. eLife 2021;0:e69679.










## Time to centrifugation



## Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients

Bente Risberg,\* <sup>††</sup> Dana W.Y. Tsui,\* <sup>†</sup> Heather Biggs, <sup>†</sup> Andrea Ruiz-Valdepenas Martin de Almagro,\* <sup>††</sup> Sarah-Jane Dawson,\* <sup>††</sup> Charlotte Hodgkin, <sup>††</sup> Linda Jones, <sup>††</sup> Chinstine Parkinson, <sup>††</sup> Anna Piskorz,\* <sup>††</sup> Francesco Marass,\* <sup>††</sup> Dineika Chandrananda,\* <sup>††</sup> Elizabeth Moore,\* <sup>††</sup> James Morris,\* <sup>††</sup> Vincent Plagnol,\* <sup>††</sup> Nitzan Rosenfeld,\* <sup>††</sup> Carlos Caldas,\* <sup>†††</sup> James D. Brenton,\* <sup>††</sup> and Davina Gale\* <sup>††</sup>

The Journal of Molecular Diagnostics, Vol. 20, No. 6, November 2018











#### Recommendations

- 1. centrifugation @ 1,600-2,500 g, 10 minutes
- Transfer supernatant to clean tube. Leave 0.5 cm above the buffycoat
- 2. centrifugation @ >10,000 g, 10 minutes
- Transfer supernatant to clean tube. Leave 0.5 cm above the pellet
- Proces within 2-4 hours if using EDTA tubes
- Long-term storage @ -80°C
- Freeze-thaw 1-2 times








### Variation





- I. Biological variation, co-morbidities, physical activity, fasting, timing in relation to medical/surgical treatment
- II. Collection tube (type/volume), syringe, stasis, first/second tube, agitation
- III. Time to centrifugation, centrifugation, temperature, pipetting, storage conditions, freeze/thaw
- IV. Extraction of DNA, (pre-amplification, denaturation, bisulphite conversion,...)







## **DNA** extraction



- Manual or automated
- Spin-column or magnetic beads
- cfDNA extraction kit







# Manual vs. automated extraction Vejle Hospital




Fig. 2. Multiple comparisons of different ccfDNA extraction methods for spike set I, based on different quantification approaches. Box plots illustrate the recovery of ccfDNA (spiked mnDNA plus donor-derived ccfDNA) from Streck (A) or PAXgene Blood ccfDNA tubes (B) among 15 extraction sites using 6 commercially available ccfDNA extraction technologies. The yield refers to the recovered nanograms of cfDNA/mnDNA from 4 mL of plasma. Yield was determined by 2 commonly used quantification assays: the qPCR-based Quantiplex Pro assay (gray) and the Fluorometric Quantitation-based Qubit assay (yellow). Moreover, ddPCR data were utilized for quantification, and all positive droplets (mutant and wild-type) from the 2 TP53 mutation ddPCR assays (R158L, light blue; R248L, blue) were combined and used to calculate the absolute yield of ccfDNA fragments. The horizontal line in each box represents the median. Two-way ANOVA multiple comparison test, \*\*P < 0.01.

Clinical Chemistry 66:1

Cancer Diagnostics

#### Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows


Rita Lampignano, <sup>1†</sup> Martin H.D. Neumann, <sup>1†</sup> Sabrina Weber, <sup>2,3</sup> Vera Kloten, <sup>1</sup> Andrei Herdean, <sup>4</sup>
Thorsten Voss, <sup>5</sup> Daniel Groelz, <sup>5</sup> Anna Babayan, <sup>6</sup> Marco Tibbesma, <sup>7</sup> Martin Schlumpberger, <sup>8</sup>
Francesca Chemi, <sup>9</sup> Dominic G. Rothwell, <sup>9</sup> Harriet Wikman, <sup>6</sup> Jean-Pierre Galizzi, <sup>10</sup>
Inger Riise Bergheim, <sup>11</sup> Hege Russnes, <sup>11</sup> Benedetta Mussolin, <sup>12</sup> Serena Bonin, <sup>13</sup> Christine Voigt, <sup>14</sup>
Hanny Musa, <sup>15</sup> Pamela Pinzani, <sup>16</sup> Evi Lianidou, <sup>17</sup> Ged Brady, <sup>9</sup> Michael R. Speicher, <sup>2</sup> Klaus Pantel, <sup>6</sup>
Fay Betsou, <sup>10</sup> Ed Schuuring, <sup>7</sup> Mikael Kubista, <sup>4</sup> Wim Ammerlaan, <sup>10</sup> Markus Spreger-Haussels, <sup>8</sup>
Thomas Schlange, <sup>1‡</sup> and Ellen Heitzer<sup>2,3+‡</sup> for the Innovative Medicines Initiative CANCER-ID Consortium








# Manual vs. automated extraction Vejle Hospital











## Magnetic beads or spin column






Table 1 Comparison of cfDNA purification kits used in this study.

cfDNA purification kit	Code for this study	Manufacturer	Kit type	Processing time (min)	Sample volume (ml)	Sample type	Price/2 ml sample in manual mode (AUD)	Automation option
QIAamp circulating nucleic acid kita	QiaS	Qiagen	Spin column	90	1–5	Plasma/serum/urine	36.78	QIAcube
Plasma/serum cell-free circulating DNA midi kit	NorS	Norgen Biotek	Spin column	80	1–4	Plasma/serum	33	Manual
QIAamp minelute ccfDNA mini kit	QiaM	Qiagen	Magnetic beads	70	1–2	Plasma/serum	18.86	QIAcube
Maxwell RSC ccfDNA plasma kit <sup>b</sup>	ProM	Promega	Magnetic beads	70	1	Plasma	31.26	Maxwell RSC
MagMax cell-free DNA isolation kit	ABioM	Applied Biosystems	Magnetic beads	70	0.1–10	Plasma/serum/urine	15.92	Kingfisher
NextPrep-Mag cfDNA isolation kit	BSciM	Bioo Scientific	Magnetic beads	60	1–3	Plasma	18.8	Chemagic 360







# Vejle Hospital - part of Lillebaelt Hospital

## Comparison of kits

- Yield
- Reproducibility
- Fragment lengths
- % tumorspecific DNA
- Double-/singlestranded DNA
- Presence of inhibitors / proteinase K
- Time of procedure, price / ml plasma, automation...









## Quality control of samples

- Yield (total DNA, exogenous purification control)
- Contamination with DNA from blood cells
- Fragment length (short vs. long fragments)
- Single- vs. doublestranded DNA








## Exogenous extraction control





CPP1 alleles in 120 plasma samples

CPP1: exogenous DNA fragment (191 bp) added to plasma samples prior to DNA extraction

Clinica Chimica Acta 446 (2015) 141-146

Contents lists available at ScienceDirect

Clinica Chimica Acta

EVIER

journal homepage: www.elsevier.com/locate/clinchim



Controls to validate plasma samples for cell free DNA quantification

CrossMark





Niels Pallisgaard  $^{\rm a,*},$  Karen-Lise Garm Spindler  $^{\rm b,c},$  Rikke Fredslund Andersen  $^{\rm a},$  Ivan Brandslund  $^{\rm a},$  Anders Jakobsen  $^{\rm b}$ 



# Vejle Hospital - part of Lillebaelt Hospital

## Fragment length

cfDNA is primarily ~160 bp. Elevated amounts of fragments >200 bp indicates contamination with DNA from blood cells.

> 136 bp assay vs. 420 bp assay After 72h, +/- shipment

Relative Amounts)

W. William F. William F.

Cong B-Actin Fragment (Relative Amounts)

With the Parkets of the Sandar Parkets of the Sandar Sanda


norgenbiotek.com








# Single- vs. doublestranded DNA Vejle Hospital - part of Lillebaelt Hospital



Fitarelli-Kiehl M et al. Clin Chem 64: 12, 1762-1771 (2018)










## Quality control of analyses









Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood

Aliaksandra Samoila,<sup>a</sup> Jose Sosa,<sup>a</sup> Jessica Padilla,<sup>a</sup> Michael Wutkowski,<sup>a</sup> Katelynd Vanness,<sup>b</sup> Agnes Viale,<sup>b</sup> Michael Berger,<sup>c</sup> Brian Houck-Loomis,<sup>b</sup> Melissa Pessin,<sup>a</sup> and Ellinor I. Peerschke<sup>a,r</sup>

JALM | 788-797 | 05:04 | July 2020

788



# Questions?





#### **Rikke Fredslund Andersen**

Biochemistry and Immunology
University Hospital of Southern Denmark, Vejle
rikke.fredslund.andersen@rsyd.dk





